Correction Open Access
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2023; 29(35): 5178-5179
Published online Sep 21, 2023. doi: 10.3748/wjg.v29.i35.5178
Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”
Supriya Roy, Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India
Suneela Dhaneshwar, Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai 410206, Maharashtra, India
ORCID number: Supriya Roy (0000-0002-8676-5113); Suneela Dhaneshwar (0000-0001-7646-642X).
Author contributions: Dhaneshwar S conceived the idea and designed the review article protocol, edited the final draft of the manuscript; Roy S collected the data and wrote the paper; and all authors reviewed and approved the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Suneela Dhaneshwar, PhD, Academic Research, Director, Pharmacist, Professor, Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai 410206, Maharashtra, India. suneeladhaneshwar@rediffmail.com
Received: August 16, 2023
Peer-review started: August 16, 2023
First decision: August 25, 2023
Revised: August 25, 2023
Accepted: September 1, 2023
Article in press: September 1, 2023
Published online: September 21, 2023

Abstract

Correction to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”. In this article, a correction note is to be added.

Key Words: Ulcerative colitis, Crohn’s disease, Pouchitis, Dysbiosis, Microbiota, Inflammation

Core Tip: This manuscript is to add a “correction note” to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”.
TO THE EDITOR

Correction to: Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29(14): 2078-2100.

In this article, a correction note is to be added[1]. The corresponding author received a mail from Dr. Claudio De Simone sharing his concern about a probiotic formulation VSL#3 which is mentioned in this review article. Dr. Claudio wishes us to publish a corrigendum. It is an earnest request that please incorporate the following correction note and publish a corrigendum regarding the same.

Correction note: This review article includes references to several studies that investigated a probiotic formulation formerly marketed as VSL#3 which is currently, generically referred to as the “De Simone Formulation”. It is important to note that the current product marketed as VSL#3 differs from the De Simone Formulation as also stated by the federal court of Maryland in the Civil Action, No. TDC-15-1356. They are distinct probiotic formulations with different compositions and characteristics. Currently, the De Simone Formulation is accessible under Vivomixx (in Europe) and Visbiome (in the United States) brand names.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: India

Peer-review report’s scientific quality classification

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Salvadori M, Italy; Zhu L, China S-Editor: Fan JR L-Editor: A P-Editor: Fan JR

References
1.  Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol. 2023;29:2078-2100.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 7]  [Cited by in F6Publishing: 27]  [Article Influence: 27.0]  [Reference Citation Analysis (0)]